IDXX Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 23.87% compared to IDEXX Laboratories's net margin of 11.12%. IDEXX Laboratories's return on equity of 57.37% beat Boston Scientific's return on equity of 8.91%.

IDEXX Laboratories has a consensus price target of $478.62, signalling upside risk potential of 15.85%. On the other hand Boston Scientific has an analysts' consensus of $99.14 which suggests that it could grow by 10.33%. Given that IDEXX Laboratories has higher upside potential than Boston Scientific, analysts believe IDEXX Laboratories is more attractive than Boston Scientific.

IDEXX Laboratories has a beta of 1.368, which suggesting that the stock is 36.778% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.802, suggesting its less volatile than the S&P 500 by 19.799%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Boston Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IDEXX Laboratories quarterly revenues are $975.5M, which are smaller than Boston Scientific quarterly revenues of $4.2B. IDEXX Laboratories's net income of $232.8M is lower than Boston Scientific's net income of $468M. Notably, IDEXX Laboratories's price-to-earnings ratio is 39.84x while Boston Scientific's PE ratio is 74.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 8.98x versus 8.37x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 23.87% compared to IDEXX Laboratories's net margin of 36.03%. IDEXX Laboratories's return on equity of 57.37% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

IDEXX Laboratories has a consensus price target of $478.62, signalling upside risk potential of 15.85%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 47.26%. Given that Regeneron Pharmaceuticals has higher upside potential than IDEXX Laboratories, analysts believe Regeneron Pharmaceuticals is more attractive than IDEXX Laboratories.

IDEXX Laboratories has a beta of 1.368, which suggesting that the stock is 36.778% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

IDEXX Laboratories quarterly revenues are $975.5M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. IDEXX Laboratories's net income of $232.8M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, IDEXX Laboratories's price-to-earnings ratio is 39.84x while Regeneron Pharmaceuticals's PE ratio is 17.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 8.98x versus 5.94x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 23.87% compared to IDEXX Laboratories's net margin of 15.18%. IDEXX Laboratories's return on equity of 57.37% beat Stryker's return on equity of 18.78%.

IDEXX Laboratories has a consensus price target of $478.62, signalling upside risk potential of 15.85%. On the other hand Stryker has an analysts' consensus of $406.60 which suggests that it could grow by 10.94%. Given that IDEXX Laboratories has higher upside potential than Stryker, analysts believe IDEXX Laboratories is more attractive than Stryker.

IDEXX Laboratories has a beta of 1.368, which suggesting that the stock is 36.778% more volatile than S&P 500. In comparison Stryker has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.217%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.87% to investors and pays a quarterly dividend of $0.80 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Stryker pays out 35.99% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IDEXX Laboratories quarterly revenues are $975.5M, which are smaller than Stryker quarterly revenues of $5.5B. IDEXX Laboratories's net income of $232.8M is lower than Stryker's net income of $834M. Notably, IDEXX Laboratories's price-to-earnings ratio is 39.84x while Stryker's PE ratio is 39.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 8.98x versus 6.42x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of 23.87% compared to IDEXX Laboratories's net margin of 28.56%. IDEXX Laboratories's return on equity of 57.37% beat Zoetis's return on equity of 48%.

IDEXX Laboratories has a consensus price target of $478.62, signalling upside risk potential of 15.85%. On the other hand Zoetis has an analysts' consensus of $214.22 which suggests that it could grow by 30.4%. Given that Zoetis has higher upside potential than IDEXX Laboratories, analysts believe Zoetis is more attractive than IDEXX Laboratories.

IDEXX Laboratories has a beta of 1.368, which suggesting that the stock is 36.778% more volatile than S&P 500. In comparison Zoetis has a beta of 0.889, suggesting its less volatile than the S&P 500 by 11.103%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.05% to investors and pays a quarterly dividend of $0.43 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Zoetis pays out 29.52% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IDEXX Laboratories quarterly revenues are $975.5M, which are smaller than Zoetis quarterly revenues of $2.4B. IDEXX Laboratories's net income of $232.8M is lower than Zoetis's net income of $682M. Notably, IDEXX Laboratories's price-to-earnings ratio is 39.84x while Zoetis's PE ratio is 30.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 8.98x versus 8.20x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.